HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dager, W. E. Articles by Gulseth, M. P. Search for Related Content PubMed PubMed Citation Articles by Dager, W. E. Articles by Gulseth, M. P.

WILLIAME. DAGER, PHARM.D., FCSHP, is Pharmacist Specialist, University of California (UC) Davis Medical Center, Sacramento; Clinical Professor of Pharmacy, School of Pharmacy, UC San Francisco; and Clinical Professor of Medicine, School of Medicine, UC Davis, Sacramento. MICHAELP. GULSETH, PHARM.D., BCPS, is Assistant Professor of Pharmacy, Department of Pharmacy, College of Pharmacy, University of Minnesota, Duluth, and Clinical Specialist, St. Mary’s Medical Center, Duluth.

Address correspondence to Dr. Dager at the Department of Pharmaceutical Services, University of California Davis Medical Center, 2315 Stockton Boulevard, Sacramento, CA 95817-2201 (william.dager{at}ucdmc.ucdavis.edu).

Purpose. This article identifies approaches for implementing an inpatient anticoagulation program involving pharmacists; two successful inpatient anticoagulation programs previously reported in the literature are described with a discussion of steps to consider in developing or expanding such a service. Summary. Two institutions implemented pharmacist-managed anticoagulation services. One institution identified an undesirable incidence of medication-related adverse events occurring in hospitalized patients receiving anticoagulants. Pharmacists were asked to assist. Pharmacist activities included the selection of anticoagulants, patient education, verification of insurance coverage of the patient’s anticoagulant, and coordination of follow-up. Physicians were available to assist. At the other institution, the department of pharmacy was asked by the orthopedic surgeons to manage warfarin for the prophylaxis against venous thromboembolism. The pharmacy department worked with the medical staff to gain approval of all policies, guidelines, and protocols to establish an anticoagulation service. Because of the success of the program, the pharmacy department expanded the service beyond warfarin. The steps to establishment of an anticoagulation service are described. The challenges facing such programs are discussed, including the potential anticoagulants in development that will create ongoing challenges in deciding which anticoagulation approach to use and in identifying patients for whom the newer agents may or may not be best suited. Conclusion. Requirements for establishing a successful inpatient anticoagulation management program included defining the pharmacist’s role in identifying patient needs, gaining support from other health care professionals, designing a program that addresses the needs of the patients, and managing unanticipated issues. Index terms: Administration; Anticoagulants; Drugs; Health-benefit programs; Interventions; Patient information; Pharmaceutical services; Pharmacists, hospital; Pharmacy, institutional, hospital; Protocols; Thromboembolism; Toxicity; Warfarin

 

This article has been cited by other articles:

				M. P. Gulseth, G. R. Grice, and W. E. Dager Pharmacogenomics of warfarin: Uncovering a piece of the warfarin mystery Am. J. Health Syst. Pharm., January 15, 2009; 66(2): 123 - 133. [Abstract] [Full Text] [PDF]

				M. Cronin, T. Hill, D. A. Reich, B. Pinard, and E. S. Krauss Implementation of a multidisciplinary, pharmacy-led, thromboprophylaxis program in total-joint arthroplasty patients Am. J. Health Syst. Pharm., January 15, 2009; 66(2): 171 - 175. [Abstract] [Full Text] [PDF]

				W. E. Dager Improving anticoagulation management in patients with atrial fibrillation Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2279 - 2280. [Full Text] [PDF]